SCHEMBL3340378

SCHEMBL3340378

CC1(C)CCC(NCCOc2ccc(-c3cccc(NC(=O)COC(=O)C(F)(F)F)c3)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
HIF1A Q16665 2/20 0.39
EPAS1 Q99814 2/20 0.39
MAPT P10636 3/20 0.39
MGLL Q99685 1/20 0.38
CDK8 P49336 1/20 0.38
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
JAK2 O60674 1/20 0.37
JAK3 P52333 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
HPGD P15428 1/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1790346 0.91 ALDH1A1 (0.42) ALDH1A1MAPTKDM4ELMNA
Trifluoroacetic Acid SCHEMBL3340376 0.85 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ETDP1HDAC1
SCHEMBL12651251 0.85 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ETDP1NPC1
Trifluoroacetic Acid SCHEMBL3338284 0.80 DPP4 (0.46) ALDH1A1KDM4ETDP1LMNA
SCHEMBL12651149 0.77 KDM1A (0.45) ALDH1A1KDM4ETSHRLMNA
SCHEMBL3338291 0.77 ALDH1A1 (0.41) ALDH1A1KDM4ETDP1SMN1; SMN2HDAC1
SCHEMBL1789424 0.76 ALDH1A1 (0.50) ALDH1A1MGLLKDM4ETDP1HDAC6
Trifluoroacetic Acid SCHEMBL1790344 0.76 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ETDP1SMN1; SMN2
SCHEMBL12651466 0.75 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ETDP1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL3343094 0.75 ALDH1A1 (0.45) ALDH1A1KDM4ETDP1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 ALDH1A1 4254/4885HIF1A 2798/4885EPAS1 2365/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 ALDH1A1 3500/4885HIF1A 2370/4885EPAS1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.